Brief: Spago Nanomedical Q3 Sales at SEK 271 Thousand
03/11/2023 07:08
Nov 3 (Reuters) - Spago Nanomedical Q3 operating expenses SEK -8.795 million. * Q3 adjusted EPS SEK -0.08 * Q3 net income SEK -7.113 million * Q3 sales SEK 271 thousand
Recent news on Spago Nanomedical AB (publ)
See all newsBrief: Spago Nanomedical Announces Outcome Of Rights Issue
Brief: Spago Nanomedical Resolves On Rights Issue Of About SEK 16 Million
Sweden's Spago Nanomedical Q1 loss narrows
Brief: Spago Nanomedical Q1 Sales SEK 22 Thousand
Brief: Spago Nanomedical Says Tumorad-01 Study Meets Primary Endpoint Of Maximum Tolerated Dose